

Prior Authorization Form

MATZIM LA (FA-PA)

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS Caremark at **1-888-836-0730**. Please contact CVS Caremark at **1-855-240-0536** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Matzim LA (diltiazem ext-rel).

Patient Information

Patient Name:	<input type="text"/>
Patient Phone:	<input type="text"/> - <input type="text"/> - <input type="text"/>
Patient ID:	<input type="text"/>
Patient Group No:	<input type="text"/>
Patient DOB:	<input type="text"/> / <input type="text"/> / <input type="text"/>

Prescribing Physician

Physician Name:	<input type="text"/>
Physician Phone:	<input type="text"/> - <input type="text"/> - <input type="text"/>
Physician Fax:	<input type="text"/> - <input type="text"/> - <input type="text"/>
Physician Address:	<input type="text"/>
City, State, Zip:	<input type="text"/> <input type="text"/> <input type="text"/>

Drug Name (specify drug): Matzim LA (diltiazem ext-rel)

Quantity: _____	Frequency: _____	Strength: _____
Route of Administration: _____	Expected Length of Therapy: _____	
Diagnosis: _____	ICD Code: _____	
Comments: _____		

Please check the appropriate answer for each applicable question.

- | | | | | |
|--|---|--------------------------|---|--------------------------|
| 1. Preferred products are available at a lower cost. Can your patient be switched to a preferred drug/ product?
Available Formulary Alternatives: <i>diltiazem ext-rel</i> (except generic of CARDIZEM LA)

[If yes, provide your patient with a new prescription for the preferred product.] | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 2. Is the requested drug being used for an FDA-Approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)? | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 3. Does the prescribed dose and quantity fall within the FDA approved labeling or within dosing guidelines found in the compendia of current literature? | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
| 4. Has the patient tried and had an inadequate treatment response or intolerance to the required number of formulary alternatives below: Drug Name, Trial Year, Reason for Failure | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |

Note: Formulary Alternatives should be prescribed first unless the patient is unable to use or receive treatment with the alternatives. Required Formulary Alternatives 1 in a class with 1 alternative: *diltiazem ext-rel* (except generic of CARDIZEM LA)

[If yes, no further questions]

- | | | | | |
|--|---|--------------------------|---|--------------------------|
| 5. Does the patient have a contraindication to all the alternatives? | Y | <input type="checkbox"/> | N | <input type="checkbox"/> |
|--|---|--------------------------|---|--------------------------|

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the claims processor, the health

plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug Pas immediately and securely online – without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.